Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changes.
10.1186/s12199-020-00871-8
- Author:
Junya MATSUSHITA
1
;
Takehiro SUZUKI
1
;
Kazuyuki OKAMURA
1
;
Gaku ICHIHARA
2
;
Keiko NOHARA
3
Author Information
1. Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan.
2. Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.
3. Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan. keikon@nies.go.jp.
- Publication Type:Journal Article
- Keywords:
DNA methylation;
Gene expression;
Hepatocellular carcinoma;
TCGA
- MeSH:
Carcinoma, Hepatocellular;
genetics;
metabolism;
Cell Proliferation;
CpG Islands;
genetics;
DNA Methylation;
Databases as Topic;
Gene Expression Regulation, Neoplastic;
Humans;
Liver Neoplasms;
genetics;
metabolism;
Promoter Regions, Genetic
- From:Environmental Health and Preventive Medicine
2020;25(1):31-31
- CountryJapan
- Language:English
-
Abstract:
BACKGROUND:Various treatments for hepatocellular carcinoma (HCC) are utilized in clinical practice; however, the prognosis is still poor on account of high recurrence rates. DNA methylation levels of CpG islands around promoters (promoter CpGis) inversely regulate gene expression and closely involved in carcinogenesis. As a new strategy, several chemicals globally inhibiting DNA methylation have been developed aiming at reducing DNA methylation levels and maintaining the expression of tumor suppressor genes. On the other hand, since these drugs nonspecifically modify DNA methylation, they can cause serious adverse effects. In order to ameliorate the methods by targeting specific CpGs, information of cancer-related genes that are regulated by DNA methylation is required.
METHODS:We searched candidate genes whose expressions were regulated by DNA methylation of promoter CpGi and which are involved in HCC cases. To do so, we first identified genes whose expression were changed in HCC by comparing gene expressions of 371 HCC tissues and 41 non-tumor tissues using the Cancer Genome Atlas (TCGA) database. The genes were further selected for poor prognosis by log-rank test of Kaplan-Meier plot and for cancer relevance by Pubmed search. Expression profiles of upregulated genes in HCC tissues were assessed by Gene Ontology (GO) analysis. Finally, using DNA methylation data of TCGA database, we selected genes whose promoter DNA methylation levels were inversely correlated with gene expression.
RESULTS:We found 115 genes which were significantly up- or downregulated in HCC tissues and were associated with poor prognosis and cancer relevance. The upregulated genes were significantly enriched in cell division, cell cycle, and cell proliferation. Among the upregulated genes in HCC, we identified hypomethylation of CpGis around promoters of FANCB, KIF15, KIF4A, ERCC6L, and UBE2C. In addition, TCGA data showed that the tumor suppressor gene P16 is unexpectedly overexpressed in many types of cancers.
CONCLUSIONS:We identified five candidate genes whose expressions were regulated by DNA methylation of promoter CpGi and associate with cancer cases and poor prognosis in HCC. Modification of site-specific DNA methylation of these genes enables a different approach for HCC treatment with higher selectivity and lower adverse effects.
